Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma
- 1 March 2001
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 37 (5), 597-604
- https://doi.org/10.1016/s0959-8049(00)00444-5
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Adjuvant or Palliative Chemotherapy for Colorectal Cancer in Patients 70 Years or OlderJournal of Clinical Oncology, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- Colorectal cancerThe Lancet, 1999
- Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer.Journal of Clinical Oncology, 1998
- Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.Journal of Clinical Oncology, 1998
- Chemotherapy for the Treatment of Patients with Metastatic Colorectal Cancer: An OverviewWorld Journal of Surgery, 1997
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancerThe Lancet, 1995
- Worldwide patterns of cancer mortality, 1985–89European Journal Of Cancer Prevention, 1994
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1992